ALVO

Add to Watchlist

Advanced Chart

0.000

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

High

9.910

Open

9.750

VWAP

Vol

331.88K

Mkt Cap

2.98B

Low

9.525

Amount

EV/EBITDA(TTM)

25.49

Total Shares

279.57M

4.10B

EV/OCF(TTM)

P/S(TTM)

4.66

Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

0.027

-108.05%

-0.002

-101.25%

0.039

-229.27%

Estimates Revision

The market is revising Upward the revenue expectations for Alvotech (ALVO) for FY2025, with the revenue forecasts being adjusted by 1.65% over the past three months. During the same period, the stock price has changed by 24.81%.

Revenue Estimates for FY2025

Revise Upward

+1.65%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.51%

In Past 3 Month

Stock Price

Go Up

+24.81%

In Past 3 Month

2 Analyst Rating

114.07% Upside

Wall Street analysts forecast ALVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALVO is 21.00 USD with a low forecast of 14.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

114.07% Upside

Current: 9.810

Low

14.00

Averages

21.00

High

28.00

114.07% Upside

Current: 9.810

Low

14.00

Averages

21.00

High

28.00

UBS

Buy

maintain

$16 -> $14

2025-07-18

Reason

UBS

Price Target

$16 -> $14

2025-07-18

maintain

Buy

Reason

UBS lowered the firm's price target on Alvotech to $14 from $16 and keeps a Buy rating on the shares. The stock is down 35% year-to-date, which UBS sees as an attractive entry point ahead of a strong second half revenue ramp, three product approvals and significant milestone payments, the analyst tells investors in a research note. The pricing pressure for b-Stelara was already reflected in the revised company guidance, UBS argues.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Alvotech SA (ALVO.O) is 28.76, compared to its 5-year average forward P/E of -22.55. For a more detailed relative valuation and DCF analysis to assess Alvotech SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-22.55

Current PE

28.76

Overvalued PE

202.08

Undervalued PE

-247.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.29

Current EV/EBITDA

15.04

Overvalued EV/EBITDA

24.93

Undervalued EV/EBITDA

-31.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

6.41

Current PS

4.17

Overvalued PS

12.20

Undervalued PS

0.62